Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity

Integrative Cancer Therapies

Volumn 10, Issue 1, 2011, Pages 47-57

  Hydock, David S ^a   Lien, Chia Ying ^a   Jensen, Brock T ^a   Schneider, Carole M ^a   Hayward, Reid ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

anthracycline; cardiomyopathy; heart failure; myosin heavy chain; SERCA2a

Indexed keywords

DOXORUBICIN; MYOSIN HEAVY CHAIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; BLOOD FLOW VELOCITY; CARDIOTOXICITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EX VIVO STUDY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; ISOLATED HEART; KINESIOTHERAPY; MALE; MITRAL VALVE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RUNNING; SITTING; THERAPY EFFECT; TREADMILL EXERCISE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; HEART DISEASES; MALE; MYOSIN HEAVY CHAINS; PHYSICAL CONDITIONING, ANIMAL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR FUNCTION, LEFT;

EID: 79953677839     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410392577     Document Type: Article

References (62)

1. Bernstein D, Fajardo G, Zhao M, et al. Differential cardioprotective/ cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol. 2005;289:H2441-H2449. (Pubitemid 41698555)
2. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol. 2006;47:182-189. (Pubitemid 44384055)
3. Hydock DS, Lien CY, Schneider CM, Hayward R. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc. 2008;40:808-817.
4. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-2636. (Pubitemid 46179451)
5. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154-171.
6. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res. 1985;19:378-382. (Pubitemid 15040580)
7. Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007;46:20-32. (Pubitemid 351182139)
8. Cole MP, Chaiswing L, Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69:186-197. (Pubitemid 41814822)
9. Alyane M, Kebsa LB, Boussenane HN, Rouibah H, Lahouel M. Cardioprotective effects and mechanism of action of polyphenols extracted from propolis against doxorubicin toxicity. Pak J Pharm Sci. 2008;21:201-209.
10. Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther. 2009;14:59-67.
11. Ramond A, Sartorius E, Mousseau M, Ribuot C, Joyeux-Faure M. Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Exp Biol Med (Maywood). 2008;233:76-83.
12. Cusack BJ, Gambliel H, Musser B, et al. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol. 2006;58:517-526.
13. Tesoriere L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994;269:430-436. (Pubitemid 24143284)
14. Berthiaume JM, Oliveira PJ, Fariss MW, Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol. 2005;5:257-267. (Pubitemid 41506867)
15. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695-699.
16. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes [published online ahead of print June 24, 2009]. Int J Cardiol. doi:10.1016/j.ijcard.2009.06.010.
17. Todorova VK, Kaufmann Y, Hennings L, Klimberg VS. Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr. 2010;140:44-48.
18. Abu-Khalaf MM, Juneja V, Chung GG, et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat. 2007;104:341-349. (Pubitemid 47231272)
19. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44. (Pubitemid 39013042)
20. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002;180:79-95. (Pubitemid 35248094)
21. Hydock DS, Wonders KY, Schneider CM, Hayward R. Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res. 2009;29:4401-4407.
22. de Beer EL, Bottone AE, van Der Velden J, Voest EE. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol. 2000;57:1152-1157. (Pubitemid 30354386)
23. Herron TJ, Korte FS, McDonald KS. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol. 2001;281:H1217-H1222.
24. Maeda A, Honda M, Kuramochi T, Takabatake T. A calcium antagonist protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Jpn Circ J. 1999;63:123-129. (Pubitemid 29080935)
25. 2+] induced by doxorubicin in cardiac cells. Eur J Pharmacol. 2001;425:117-120.
26. Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, Cusack BJ. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol. 2005;5:269-283. (Pubitemid 41506868)
27. Arai M, Yoguchi A, Takizawa T, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)- ATPase gene transcription. Circ Res. 2000;86:8-14. (Pubitemid 30044162)
28. Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJ. Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol. 1985;59:1298-1303. (Pubitemid 16195344)
29. Chicco AJ, Hydock DS, Schneider CM, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006; 100:519-527. (Pubitemid 43671603)
30. Talmadge RJ, Roy RR. Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol. 1993;75:2337-2340. (Pubitemid 23352414)
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
32. Aragno M, Mastrocola R, Medana C, et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology. 2006;147:5967-5974. (Pubitemid 44833515)
33. French JP, Quindry JC, Falk DJ, et al. Ischemia-reperfusion-induced calpain activation and SERCA2a degradation are attenuated by exercise training and calpain inhibition. Am J Physiol Heart Circ Physiol. 2006;290:H128-H136.
34. Emter CA, McCune SA, Sparagna GC, Radin MJ, Moore RL. Low-intensity exercise training delays onset of decompensated heart failure in spontaneously hypertensive heart failure rats. Am J Physiol Heart Circ Physiol. 2005;289:H2030-H2038. (Pubitemid 41507354)
35. Edes IF, Toth A, Csanyi G, et al. Late-stage alterations in myofibrillar contractile function in a transgenic mouse model of dilated cardiomyopathy (Tgalphaq*44). J Mol Cell Cardiol. 2008;45:363-372.
36. Zhong Y, Reiser PJ, Matlib MA. Gender differences in myosin heavy chain-beta and phosphorylated phospholamban in diabetic rat hearts. Am J Physiol Heart Circ Physiol. 2003;285:H2688-H2693. (Pubitemid 37443090)
37. Krenz M, Sanbe A, Bouyer-Dalloz F, et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem. 2003;278:17466-17474. (Pubitemid 36799633)
38. Korte FS, Herron TJ, Rovetto MJ, McDonald KS. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol. 2005;289:H801-H812. (Pubitemid 41129398)
39. Herron TJ, McDonald KS. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002;90:1150-1152. (Pubitemid 34786898)
40. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol. 2000;278:H412-H419. (Pubitemid 30131239)
41. Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats - relevance for mitochondrial dysfunction. Toxicology. 2006;220:160-168. (Pubitemid 43276405)
42. Morris GS, Prevost MC, Nelson AG. Morderate diabetes alters myosin isoenzyme distribution in cardiac but not skeletal muscle of male rats. Life Sci. 1996;58:833-838. (Pubitemid 26075755)
43. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-1700. (Pubitemid 34712910)
44. Konorev EA, Vanamala S, Kalyanaraman B. Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol Med. 2008; 45:1723-1728.
45. Ueno M, Kakinuma Y, Yuhki K, et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci. 2006;101:151-158. (Pubitemid 43938766)
46. Jang YM, Kendaiah S, Drew B, et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett. 2004;577:483-490. (Pubitemid 39539206)
47. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz). 2009;57:435-445.
48. 2+ increase and apoptosis in rat cardiomyocytes. Biol Pharm Bull. 2008;31:809-815.
49. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med. 2006;38:535-545.
50. 2+ regulation in rats with doxorubicin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44:2239-2246.
51. Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol. 2006;23:71-80. (Pubitemid 41769977)
52. Iarussi D, Pisacane C, Indolfi P, Casale F, Martino V, Di Tullio MT. Evaluation of left ventricular function in longterm survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2005;45:700-705. (Pubitemid 41279363)
53. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 2005;289:R424-R431. (Pubitemid 41060497)
54. Ascensao A, Magalhaes J, Soares J, et al. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol. 2005;100:451-460.
55. Jin H, Yang R, Li W, et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am J Physiol Heart Circ Physiol. 2000;279:H2994-H3002. (Pubitemid 32005891)
56. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI. Alterations in myocardial cytoskeletal and regulatory protein expression following a single doxorubicin injection. J Cardiovasc Pharmacol. 2003;41:788-794. (Pubitemid 36523183)
57. Andersson KB, Birkeland JA, Finsen AV, et al. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol. 2009;47:180-187.
58. Barry WH. Molecular inotropy: a future approach to the treatment of heart failure? Circulation. 1999;100:2303-2304.
59. Mayosi BM, Kardos A, Davies CH, et al. Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure. Heart. 2006;92:105-109. (Pubitemid 43021870)
60. Lu L, Mei DF, Gu AG, et al. Exercise training normalizes altered calcium-handling proteins during development of heart failure. J Appl Physiol. 2002;92:1524-1530. (Pubitemid 34670908)
61. Shao CH, Wehrens XH, Wyatt TA, et al. Exercise training during diabetes attenuates cardiac ryanodine receptor dysregulation. J Appl Physiol. 2009;106:1280-1292.
62. Noble EG, Moraska A, Mazzeo RS, et al. Differential expression of stress proteins in rat myocardium after free wheel or treadmill run training. J Appl Physiol. 1999;86:1696-1701. (Pubitemid 29230318)